Reduced expression of SOX9 and EGR2 in AML-MSCs as compared with ND-MSCs was validated by qRT-PCR (Fig. 4a) and western blot analysis (Fig. 4b, c). This evidence concerns the gene EGR2 and acute myeloid leukemia.